



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/632,340
Confirmation No.: 3588
Filing Date: August 1, 2003
Examiner: Venkataraman Balasubramanian
Group Art Unit: 1624
Applicants: Forster et al.
For: COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3

July 13, 2006
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copies of references Citation Nos. **B1-B12, C1-C7** are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

- (b) ☐ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.


Applicants: Forster et al.
Application No.: VPI/02-119 US

- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
 - ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
 - ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
 - ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
 - ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
 - ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
 - ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

Applicants: Forster et al.
Application No.: VPI/02-119 US

- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,




Jennifer G. Che, Reg. No. 58,035
Agent for Applicants
Lisa A. Dixon, Reg. No. 40,995
Attorney for Applicants
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6525
Fax: (617) 444-6483

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450 on July 13, 2006.



Fareesha Ali



Revised Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/632,340
Filing Date	August 1, 2003
First Named Inventor	Cornelia J. Forster
Group Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/02-119 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue/Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,051,252	09/27/1977	Mayer, et al.			
	A2	3,935,183	01/27/1976	Baron, et al.			
	A3	3,133,081	05/12/1964	Lafferty, et. al.			
	A4	3,998,951	12/21/1976	Harnish, et al.			
	A5	4,493,726	01/15/1985	Brudeska, et al.			
	A6	5,972,946	10/26/1999	Murata, et al.			
	A7	20050004110	01/06/2005	Bebbington et al			
	A8	20030073687	04/17/2003	Bebbington et al			
	A9	20030055044	03/20/2003	Davies et al			
	A10	20030064982	04/03/2003	Davies et al			
	A11	20030083327	05/01/2003	Davies et al			
	A12	20040097501	05/20/2004	Bebbington et al			
	A13	20030078275	04/23/2003	Bebbington et al			
	A14	20030055068	03/20/2003	Bebbington et al			
	A15	20030036543	02/20/2003	Bebbington et al			
	A16	20040214814	10/28/2004	Bebbington et al			
	A17	20030004161	01/02/2003	Bebbington et al			
	A18	20030105090	06/05/2003	Bebbington et al			
	A19	20030022885	01/30/2003	Bebbington et al			
	A20	20030004164	01/02/2003	Bebbington et al			
	A21	20040002496	01/01/2004	Bebbington et al			
	A22	20030225073	12/04/2003	Bebbington et al			
	A23	20040009974	01/15/2004	Bebbington et al			
	A24	20040009981	01/15/2004	Bebbington et al			

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/632,340
	Filing Date	August 1, 2003
	First Named Inventor	Cornelia J. Forster
	Group Art Unit	1624
	Examiner Name	Venkataraman Balasubramanian
	Attorney Docket Number	VPI/02-119 US

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	JP 2000-26421	Kumiai Chemical	25-Jan-2000		X	
	B2	WO 00/21955	Zeneca Limited	20-Apr-2000			
	B3	WO 00/39101	Astra Zeneca UK Limited	06-Jul-2000			
	B4	WO 98/14450	Novartis AG	09-Apr-1998			
	B5	WO 95/15758	Rhone Poulenc Rorer Pharmaceuticals Inc.	15-Jun-1995			
	B6	WO 99/62518	Cadus Pharmaceutical Corporation	09-Dec-1999			
	B7	WO 93/22681	Neurogen Corporation	11-Nov-1993			
	B8	WO 01/60816	Amgen Inc.	23-Aug-2001			
	B9	WO 02/18346	Pfizer Products Inc.	07-Mar-2002			
	B10	DT 2458965	Bayer AG	16-Jun-1976			
	B11	WO 00/42029	Warner-Lambert Company	20-July-2000			
	B12	WO 98/02434	Glaxo Group Limited	22-Jan-1998			

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Medwid, J.B., et al., "Preparation of Triazolo[1,5-c] pyrimidines as Potential Antiasthma Agents", <i>J. Med. Chem.</i> , 33:1230-1241 (1990).
	C2	Traxler, P., et al., "Use of Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: Phenylamino)pyrazole [3,4-d]pyrimidines", <i>J. Med. Chem.</i> , 40:3601-3616 (1997).
	C3	Parnell, E.W., "2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroindazole", <i>J. Chem. Soc.</i> , 2363-2365 (1959).
	C4	Partridge, M. W., et al., "Cyclic Amidines, Part XXII. Novel Isomerism of Disubstituted Tri-cycloquinazolines and Molecular Orientations in Carcinogenesis", <i>J. Chem. Soc.</i> , 19:2641-2647 (1970).
	C5	Baig, G.U., et al., "Triazines and Related Products. Part 27 ¹ . Thermolysis of 4-Anilino-1,2,3-benzotriazines", <i>J. Chem. Soc. Perkin Trans. 1</i> (5):999-1003 (1984).
	C6	Ivashchenko, A.V. et al: "Synthesis and study of heteroaromatic ligands containing a pyrimidine ring" <i>Khim. Geterotsikyl. Soedin.</i> (12) 1673-7 (1980).
	C7	Traxler, P. <i>Exp. Opin. Ther. Targets</i> 7(2):215-234 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.